High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Investing.com -- Novo Nordisk (CSE:NOVOb) (NYSE:NVO) hiked its full-year guidance, saying annual sales and operating profit should decline less than previously expected as demand for its weight-loss drugs continues unabated.
Novo now expects underlying sales and operating profit in the range of 0% to –6% for the year.
U.S.-traded shares of Novo Nordisk are down more than 6% due to a sales shortfall for its new Wegovy weight-loss pill and a disappointing study outcome for a next-generation weight-loss drug. Overall, the company sees the potential for a full-year sales decline of up to 6%, better than its previous view that sales could drop up to 12%. Novo also disclosed that its experimental drug CagriSema failed to show comparable blood-sugar reduction to Eli Lilly’s tirzepatide in a new study of people with Type 2 diabetes.
Novo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early.
Novo Nordisk shares dropped after the Danish drugmaker said an experimental medicine didn't reduce risk of major adverse cardiovascular events in a late-stage trial. The company's Denmark-listed stock was down nearly 10%, while its American depositary receipts fell about 9% in premarket trading in New York.
Investing.com -- Novo Nordisk (NYSE: NVO) shares dropped 10% Friday after the drugmaker revealed its experimental drug, ziltivekimab, failed to cut cardiovascular risk in a late-stage clinical trial.
The stock was down 9.5% after the company’s experimental medicine ziltivekimab didn’t achieve the expected risk reduction for major cardiovascular events.
Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.
Novo alleges that Lilly’s Zepbound advertisements compare the drug’s highest approved dose with lower doses of Wegovy.
European stock markets fell in late Tuesday trading as oil prices rose after negotiations between th
By Amina Niasse and Siddhi Mahatole May 11 (Reuters) - Hims & Hers Health missed Wall Street estimates for first-quarter revenue and posted a surprise loss on Monday, as the telehealth company's shift
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
